Scientific area
3.1 Basic medicine
Discipline(s)
Toxicology
Pharmacology and pharmacy
Neurosciences (including psychophysiology)
Project title
Preventing Memory Loss in Alzheimer’s Disease: Underlying Mechanisms and Therapeutic Targets of Tauroursodeoxycholic Acid
Scientific Coordinator's name:
Cecília Maria Pereira Rodrigues
Scientific Coordinator's e-mail:
cmprodrigues@ff.ul.pt
Principal R&D Unit:
iMed.UL/FFUL
Other R&D Units involved in the project:
University of Minnesota Medical School, Department of Medicine and Genetics, Cell Biology, and Development (UM) Catholic University of Leuven, Belgium (KULeuven)
Project keyword(s)
Amyloid-beta; APP/PS1 double transgenic; Neuroprotection; miRNAs
Short abstract and comments
Alzheimer’s disease is a neurodegenerative disease characterized by accumulation of toxic amyloid-beta in the frontal cortex and hippocampus, with progressive cognitive decline. However, little is known about the mechanisms that contribute to Abeta load in the vast majority of sporadic Alzheimer’s disease. This project aims at determining whether targeting signal transduction pathways and gene and protein networks in amyloid-beta metabolism by tauroursodeoxycholic acid can be used therapeutically to arrest the pathogenesis of Alzheimer’s disease.
Potential uses/indications
This project will increase our appreciation of the gene and protein networks that mediate Abeta metabolism and pathology, which will be crucial for developing novel and potent therapeutic approaches to overcome the current lack of successful therapies in Alzheimer’s disease.
Status
Ongoing
Partner Status: Seeking Partners?
No
Grant number (QREN, FP7, Eureka, etc)
PTDC/SAU-NMC/117877/2010
Last edited on
2013-11-04 13:02:11